logo-loader
viewEmerald Clinics Ltd

Emerald Clinics sees potential in filling evidence gap for cannabinoid products

Emerald operates a network of clinics specialised in assessing the safety and efficacy of unregistered medicines including cannabinoid medicines.

Emerald Clinics Ltd - Emerald Clinics sees potential in filling evidence gap for cannabinoid products
The company collects robust and ethically sourced real-world evidence

Emerald Clinics Ltd (ASX:EMD) is different from its cannabis sector peers in that it operates specialist cannabis clinics for patients to gather real-world evidence.

There is a massive evidence gap for cannabinoid products and this creates significant challenges for stakeholder adoption

The company opened its first clinic in Perth’s West Leederville in December 2018 and now has three more, in Sydney’s Woolloomooloo, Richmond in Melbourne and Tintenbar in New South Wales.

Emerald’s growth prospects lie not only in consultation fees but accruing data on how the patients are faring under the various drugs and dosages.

The company’s plan is to sell this growing data to parties such as drug developers, who can use the stats as an alternative to expensive formal clinical trials.

Emerald’s evidence generating care model

Emerald managing director and chief executive officer Dr Michael Winlo recently said: “We believe robust and ethically-sourced clinical evidence is vital for medicinal cannabis to be considered a mainstream medicine and Emerald is well-positioned to be a key supplier of this information covering appropriate prescribing and safe monitoring.”

Emerald’s potential revenue streams

Emerald recently entered into a clinical trial research agreement with Zelira Therapeutics Ltd (ASX:ZLD) to test a medicinal cannabinoid oil formulation in chronic pain participants.

The first of its kind clinical trial is designed with a primary end-point of assessing the efficacy of a full spectrum plant-derived cannabis formulation containing THC and CBD to reduce opioid dependence in chronic non-cancer patients.

Chronic pain patients in Australia – market size

Quick facts: Emerald Clinics Ltd

Price: 0.06 AUD

ASX:EMD
Market: ASX
Market Cap: $11.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Emerald Clinics Ltd named herein, including the promotion by the Company of Emerald Clinics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Emerald Clinics gears up for an IPO

Emerald Clinics Ltd chief executive officer and managing director Dr Michael Winlo updates Proactive on the healthcare technology and services company’s science-driven and data-underpinned approach in the complex world of care. The CEO spoke about what drives the company, how it creates...

on 20/12/19

2 min read